Clinical trials: Neurogenetic Disorders
- Condition Neurogenetic Disorders
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer's Disease
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
This study involves the use of an investigational drug called NGP 555. In each group of healthy subjects, 2 people will receive placebo and 6 people will receive NGP 555.
- Trial name
- NCT02537938
- Testing
- NGP 555
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NeuroGenetic Pharmaceuticals Inc
Alzheimer's Disease
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
NGP 555 is a small molecule preventative therapy aimed at reducing Alzheimer's disease amyloid buildup by targeting Abeta 42 production.
- Trial name
- NCT02534480
- Testing
- NGP 555
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuroGenetic Pharmaceuticals Inc